Your browser doesn't support javascript.
loading
Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis.
Sarwar, Muhammad Usman; Waasia, Fathimathuz Zehra; Aloqbi, Akram Ahmed; Alandiyjany, Maher; Alqahtani, Reem Mohammed; Hafiz, Lubna Abdulrahman; Shamlan, Ghalia; Albreiki, Mohammed.
Afiliación
  • Sarwar MU; Department of Statistics, University of Gujrat, Pakistan.
  • Waasia FZ; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates.
  • Aloqbi AA; Department of Biology, Faculty of Science, University of Jeddah, Jeddah, Saudi Arabia.
  • Alandiyjany M; Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia; Quality and Development Affair, Batterjee Medical College, Jeddah, Saudi Arabia.
  • Alqahtani RM; Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Hafiz LA; Fakeeh College of Medical Science, Jeddah, Saudi Arabia.
  • Shamlan G; Department of Human Nutrition, College of food science and agriculture, King Saud University, Riyadh, Saudi Arabia. Electronic address: Shamlana@ksu.du.sa.
  • Albreiki M; Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates; Biosecurity Affairs Division, Innovation and Development Sector, Abu Dhabi Agriculture and Food Safety Authority, Abu Dhabi, United Arab Emirates. Electronic address: m.albreiki1987@gmail.com.
J Infect Public Health ; 17(2): 245-253, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38141544
ABSTRACT

BACKGROUND:

COVID-19 has killed over 6 million people worldwide, making it the worst global health disaster since the 1918 influenza pandemic. Experts have worked to establish the source, track and analyse the disease, and produce treatment and preventative guidelines. Inactivated vaccines have little evidence of efficacy compared to mRNA and adenoviral vector vaccines; however, three doses of both mRNA and inactivated vaccines appear to provide significant and lasting protection against severe disease and mortality. This study examines inactivated vaccine effectiveness data by disease status, age, gender, primary immunisation, booster doses, and SARS-CoV2 virus types.

METHODS:

We conducted a quantitative epidemiological meta-analysis study to assess the vaccine effectiveness of inactivated COVID-19 vaccines. Data extraction was performed on the selected studies, and data analysis was conducted using a random-effects model to determine consolidated assessments of vaccine effectiveness. Subgroup analyses were conducted for gender, age, disease level, and vaccine status, and sensitivity analyses were conducted to assess the robustness of the results.

RESULTS:

The overall effect size of inactivated COVID-19 vaccinations was statistically significant (p-value<0.05), suggesting that complete vaccination should be the primary method of vaccination. Partial vaccination was associated with lower levels of vaccine effectiveness (70.18 95% CI 57.33-83.02) than complete vaccination (79.52 95% CI 67.88-91.71)) and booster vaccination (84.22 95% CI 74.34-94.10), suggesting that it is essential to finish the recommended vaccine series and receive booster doses. Fig.-3 Partially vaccinated individuals showed a vaccine effect size of 70.18 (95% CI 57.33-83.02), indicating that the vaccine was moderately effective in preventing COVID-19 among this group. Fully vaccinated individuals showed a vaccine effect size of 79.52 (95% CI 67.88-91.71), indicating a higher level of vaccine effectiveness. Finally, booster-vaccinated individuals showed a vaccine effect size of 84.22 (95% CI 74.34-94.10), indicating the highest level of vaccine effectiveness.

CONCLUSION:

Inactivated COVID-19 vaccines are highly effective in preventing COVID-19, and complete vaccination and booster vaccination are associated with higher levels of vaccine effectiveness compared to partial vaccination. These findings highlight the importance of completing the recommended vaccine series and receiving booster doses to provide greater protection against COVID-19.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: J Infect Public Health Asunto de la revista: DOENCAS TRANSMISSIVEIS / SAUDE PUBLICA Año: 2024 Tipo del documento: Article País de afiliación: Pakistán

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: J Infect Public Health Asunto de la revista: DOENCAS TRANSMISSIVEIS / SAUDE PUBLICA Año: 2024 Tipo del documento: Article País de afiliación: Pakistán